Please assess the completion status of the following clinical trial:

Trial Title: Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women between 18 and 50 years old~* Cutaneous ulcers of more than two weeks of evolution~* Positive parasitological diagnosis for CL~* Patients that voluntarily agree to participate in the study and sign the informed consent.~* Disposition to attend all the visits punctually (initial, treatment and follow-up)~* Acceptation of not using any other treatment for CL while in the study~Exclusion Criteria:~* Pregnant women~* Presence of any condition or disease that compromises the patient immunologically (i.e. diabetes, cancer, etc.) or, any other, that, based on the judgment of the researcher, could alter the course of CL.~* Diffuse CL or more than five active lesions.~* Mucocutaneous leishmaniasis (no lesion must be located less than 2 cm from the nasal, uro-genital, and/or anal mucous membranes or from the edge of the lips).~* Visceral leishmaniasis~* Complete or incomplete treatment with antimony compounds in the last three months.~* Patients with history of hepatic, renal or cardiovascular disease.~* Mentally or neurologically disabled patients that are considered not fit to approve their participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).